Q3 2023 Results slide image

Q3 2023 Results

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology Neuroscience Conclusions Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 62 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation